Translates biological understanding to cancer therapy

Ectin Research offers a combination therapy MFA-370 consisting of two, highly utilized and with limited or no side effects, pharmaceuticals that will facilitate the developmental process to product. The aim is to focus initially on treating metastasizing bladder cancer to prove the efficacy of the therapy, and to explore the treatment of other indications further on.

Impact: New treatment for metastasizing bladder cancer
Stage: Late pre-clinica/Clinical stage
CEO: Anna Sjöblom-Hallén
GUV Contact: Anders Waas